JP2003528614A - 肝炎ウイルスのｏｒｆ２のｎ末端領域に由来するプロセシング成分および抗原性ポリペプチドをコードする核酸構築物 - Google Patents

肝炎ウイルスのｏｒｆ２のｎ末端領域に由来するプロセシング成分および抗原性ポリペプチドをコードする核酸構築物

Info

Publication number
JP2003528614A
JP2003528614A JP2001570795A JP2001570795A JP2003528614A JP 2003528614 A JP2003528614 A JP 2003528614A JP 2001570795 A JP2001570795 A JP 2001570795A JP 2001570795 A JP2001570795 A JP 2001570795A JP 2003528614 A JP2003528614 A JP 2003528614A
Authority
JP
Japan
Prior art keywords
nucleic acid
processing
processing component
seq
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001570795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528614A5 (enExample
Inventor
ファン リー
デビッド アンドリュー アンダーソン
ダミアン フランシス ジョン パーシル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Original Assignee
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macfarlane Burnet Institute for Medical Research and Public Health Ltd filed Critical Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Publication of JP2003528614A publication Critical patent/JP2003528614A/ja
Publication of JP2003528614A5 publication Critical patent/JP2003528614A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2001570795A 2000-03-31 2001-03-30 肝炎ウイルスのｏｒｆ２のｎ末端領域に由来するプロセシング成分および抗原性ポリペプチドをコードする核酸構築物 Withdrawn JP2003528614A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU6616 2000-03-31
AUPQ6616A AUPQ661600A0 (en) 2000-03-31 2000-03-31 A nucleic acid construct and methods related thereto
PCT/AU2001/000353 WO2001073078A1 (en) 2000-03-31 2001-03-30 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide

Publications (2)

Publication Number Publication Date
JP2003528614A true JP2003528614A (ja) 2003-09-30
JP2003528614A5 JP2003528614A5 (enExample) 2008-05-15

Family

ID=3820712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001570795A Withdrawn JP2003528614A (ja) 2000-03-31 2001-03-30 肝炎ウイルスのｏｒｆ２のｎ末端領域に由来するプロセシング成分および抗原性ポリペプチドをコードする核酸構築物

Country Status (14)

Country Link
US (1) US7341723B2 (enExample)
EP (1) EP1274851B1 (enExample)
JP (1) JP2003528614A (enExample)
KR (1) KR100768051B1 (enExample)
CN (1) CN1426472A (enExample)
AT (1) ATE430804T1 (enExample)
AU (1) AUPQ661600A0 (enExample)
CA (1) CA2407036A1 (enExample)
DE (1) DE60138612D1 (enExample)
HK (1) HK1052368A1 (enExample)
MX (1) MXPA02009437A (enExample)
NZ (1) NZ521758A (enExample)
WO (1) WO2001073078A1 (enExample)
ZA (1) ZA200207769B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004761A2 (en) 2002-07-05 2004-01-15 Denis Leclerc Adjuvant viral particle
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
KR100641810B1 (ko) * 2004-04-23 2006-11-06 주식회사 포스코건설 충격흡수 및 복원 가능한 중간 스프링 설치 금속재 지주
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
EP2400982B1 (en) * 2009-02-27 2016-05-11 The Regents of The University of California Multiple antigen delivery system using hepatitis e virus-like particle
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle

Also Published As

Publication number Publication date
US7341723B2 (en) 2008-03-11
EP1274851B1 (en) 2009-05-06
EP1274851A1 (en) 2003-01-15
WO2001073078A1 (en) 2001-10-04
EP1274851A4 (en) 2004-12-08
HK1052368A1 (zh) 2003-09-11
DE60138612D1 (de) 2009-06-18
MXPA02009437A (es) 2006-05-25
KR100768051B1 (ko) 2007-10-18
ATE430804T1 (de) 2009-05-15
KR20030015223A (ko) 2003-02-20
AUPQ661600A0 (en) 2000-05-04
CA2407036A1 (en) 2001-10-04
CN1426472A (zh) 2003-06-25
US20030158138A1 (en) 2003-08-21
ZA200207769B (en) 2004-02-10
NZ521758A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
US11911462B2 (en) Nucleic acid vaccine against the SARS-CoV-2 coronavirus
JP7083362B2 (ja) セネカウイルスａ免疫原性組成物およびその方法
TWI620574B (zh) 口蹄疫合成胜肽緊急疫苗
US20220105170A1 (en) African swine fever vaccine
CA2526128A1 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
WO2022110099A1 (en) Coronavirus vaccines and uses thereof
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
JP2018523993A (ja) Ｐｒｒｓｖ微量タンパク質含有組換えウイルスベクター並びにその作製及び使用方法
WO2021262672A1 (en) Sars-cov-2 rbd constructs
JP2020534284A (ja) ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法
TW202334198A (zh) 用於避免感染與治療遠程新冠肺炎之針對SARS-CoV-2 OMICRON BA.4/BA.5的疫苗組成物
CN118043451A (zh) 疫苗抗原
Mingxiao et al. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18
US20230330211A1 (en) Compositions and methods for treating and preventing coronaviruses
KR20230005265A (ko) Sars-cov-2에 대한 백신 및 이의 제조
JP2003528614A (ja) 肝炎ウイルスのｏｒｆ２のｎ末端領域に由来するプロセシング成分および抗原性ポリペプチドをコードする核酸構築物
US20230053555A1 (en) Mumps and measles virus immunogens and their use
EP4210741A1 (en) Vaccine for viral pathogens
US20240131148A1 (en) Immunogenic compositions
AU2001243941B2 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
US20130273170A1 (en) Puumala virus full-length m segment-based dna vaccines
US20250249088A1 (en) THERAPEUTIC AND VACCINE CANDIDATES AGAINST SARS-CoV-2
AU2001243941A1 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
TW202330575A (zh) 用於治療及預防冠狀病毒之組成物及方法
WO2022149609A1 (ja) Ｍｈｃ分子に適合する病原微生物由来のペプチドが担持された複合蛋白質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン、並びに、免疫後の生理活性物質の分泌に関する情報の取得方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080327

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090213

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091211